Lobbying

Medical Group Management Assn's latest lobbying report covers Q2 2026, at $300K. The four quarters Q4 2025–Q3 2026 total $900K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.

Medical Group Management Assn

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$900K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Medical Group Management Assn lobbying by quarter
Medical Group Management Assn lobbying by quarter
QuarterAmountReports
Q4 2022$300K1
Q1 2023$300K1
Q2 2023$300K1
Q3 2023$300K1
Q4 2023$300K1
Q1 2024$300K1
Q2 2024$300K1
Q3 2024$300K1
Q4 2024$300K1
Q1 2025$300K1
Q2 2025$300K1
Q3 2025$300K1
Q4 2025$300K1
Q1 2026$300K1
Q2 2026$300K1
Q3 2026$00

By issue

  • Health issues$2.3M · 15 reports
  • Medicare and Medicaid$2.3M · 15 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • Centers For Medicare and Medicaid Services (CMS)15 reports
  • Health & Human Services, Dept of (HHS)15 reports
  • HOUSE OF REPRESENTATIVES15 reports
  • SENATE15 reports
  • Drug Enforcement Administration (DEA)5 reports
  • Homeland Security, Dept of (DHS)3 reports
  • Consumer Financial Protection Bureau (CFPB)2 reports
  • Labor, Dept of (DOL)2 reports
  • Office of Management & Budget (OMB)2 reports
  • Treasury, Dept of2 reports
  • Education, Dept of1 reports
  • Food & Drug Administration (FDA)1 reports
  • Office of Science & Technology Policy (OSTP)1 reports
  • State, Dept of (DOS)1 reports
  • White House Office1 reports

Firms it paid

Firm
In-houseMedical Group Management Assn$4.5M15 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
07/20for Q2In-house$300K
04/20for Q1In-house$300K
01/20for Q4 2025In-house$300K
25/10/20for Q3 2025In-house$300K
25/07/21for Q2 2025In-house$300K
25/04/21for Q1 2025In-house$300K
25/01/21for Q4 2024In-house$300K
24/11/08for Q3 2024In-house$300K
24/07/30for Q2 2024In-house$300K
24/04/19for Q1 2024In-house$300K
24/01/19for Q4 2023In-house$300K
23/10/20for Q3 2023In-house$300K
23/07/20for Q2 2023In-house$300K
23/04/13for Q1 2023In-house$300K
23/01/20for Q4 2022In-house$300K